Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian CancerJune 14th 2022
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
Off-the-Shelf Cervical Cancer Vaccine Shows Promising Initial Results in HPV16+ PatientsMay 13th 2022
Atezolizumab in conjunction with VB10.16, the first off-the-shelf therapeutic cancer vaccine, elicited encouraging responses in pretreated patients with HPV16-positive advanced cervical cancer.
Olaparib Dosage Can Be Reduced Without Affecting Survival in Ovarian CancerApril 18th 2022
New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.
FDA Follow-Up: Utilizing Pembrolizumab for MSI-H/dMMR Advanced Endometrial CarcinomaApril 8th 2022
Courtney Arn, APRN-CNP, a nurse practitioner who supported cohorts D and K of the KEYNOTE-158 study, discusses the recent approval of pembrolizumab for patients with MSI-H/dMMR advanced endometrial carcinoma.
Niraparib/Bevacizumab Combo Elicits Promising Responses in Advanced Ovarian Cancer, Regardless of Biomarker StatusMarch 31st 2022
The PARP inhibitor, niraparib, in conjunction with the VEGF inhibitor, bevacizumab, resulted in encouraging responses from patients with advanced ovarian cancer.
Patient-Reported Outcomes Demonstrate Satisfaction With Pembrolizumab in Advanced Cervical CancerMarch 27th 2022
Data collected with patient-reported outcomes show that pembrolizumab, with or without bevacizumab, is associated with a favorable toxicity profile in effectively treating women with persistent, recurrent, or metastatic cervical cancer.
Adding Atezolizumab to Chemoradiation Promotes T-Cell Clonal Expansion in Node-Positive Cervical CancerMarch 26th 2022
Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.
Maintenance Selinexor Yields Survival Benefit in Advanced or Recurrent Endometrial CancerMarch 23rd 2022
Selinexor demonstrated impressive efficacy in extending progression-free survival among patient with advanced or recurrent endometrial cancer, particularly among patients with wild-type p53 endometrial cancer.
Investigators Set to Assess Novel Immunotherapy/Chemo Combo in Advanced Ovarian CancerMarch 21st 2022
The ongoing FLORA-5 trial will assess whether the addition of oregovomab to a standard chemotherapy regimen will improve progression-free and overall survival in patients with advanced epithelial ovarian cancer.
Secondary Cytoreductive Surgery Only Offers Benefit to Select Patients With Ovarian CancerFebruary 2nd 2022
An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.
Upifitamab Rilsodotin May Answer Questions in Platinum-Resistant Recurrent Ovarian CancerFebruary 2nd 2022
An expert from Arizona Oncology discusses the unmet need for agents to address recurrent ovarian cancer and how upifitamab rilsodotin, an antibody-drug conjugate with promising preclinical and clinical data, may play into the treatment paradigm.
High Rate of High-Risk Endometrial Cancer in Black Women Demands Attention and Further Research Into Underlying DisparitiesFebruary 1st 2022
An expert from the University of California Los Angeles (UCLA) discusses the alarming rate of high-risk uterine cancers among Black women and how researchers are investigating the underlying risk factors at play.
Olaparib Plus Temozolomide Induces Promising Response Duration in Uterine LeiomyosarcomaJanuary 8th 2022
The use of PARP inhibitor olaparib in conjunction with temozolomide may be an effective treatment for patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype.
Lenvatinib/Pembrolizumab Combo Continues to Show Benefit in Advanced Endometrial CancerNovember 21st 2021
A presentation at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting shared updated findings on the efficacy of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
Inguinofemoral Radiotherapy May Be Potential Alternative To Lymphadenectomy In Select Vulvar CancerOctober 21st 2021
Inguinofemoral radiotherapy may be a safe alternative for patients with vulvar cancer and sentinel node micrometastases who might otherwise face the morbidity of a lymphadenectomy.
Strategies That Combine Immunotherapies With Bevacizumab, Other Agents May Expand Utility of Immunotherapy in Recurrent Ovarian CancerOctober 10th 2021
Combining immunotherapy with other targeted therapies may result in more promising outcomes than immunotherapy alone in the treatment of recurrent ovarian cancer, according to an expert at University of California, Los Angeles.